A PYMNTS Company

UK: US pharma firm strikes a deal with Convergence

By  |  January 14, 2015

Massachusetts-based pharmaceutical company Biogen Idec has agreed to acquire UK based Convergence Pharmaceuticals (CP).

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    CP is a clinical-stage biopharmaceutical company and the acquisition is centered on a drug it is testing that is for treating a chronic pain disease called trigeminal neuralgia ,which consists of episodic, debilitating facial pain. CP would initially receive $200 million with an additional $475 million paid dependant on future milestones.

    The acquisition is still subject to closing conditions from the UK and the US, including the waiting period required by the Hart-Scott-Rodino Antitrust Improvements Act from the US. The companies are not expecting any major difficulties and are hoping for the acquisition to clear within the first quarter of 2015.

    Full Content: Post Online Media

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.